BackOpus Genetics Overview
Opus Genetics, Inc.

Opus Genetics Target Price

See Opus Genetics's analyst price targets ($13) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$4.64

Average Target Price

$12.60171.6% upside

5 analysts in the last 4 months

High: $20 | Low: $8

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-09Chardan CapitalAndreas Argyrides$16244.8% upsideOpen
2026-09-09Oppenheimer$20331% upsideOpen
2026-08-07RBC Capital$994% upsideOpen
2026-06-23RBC Capital$10115.5% upsideOpen
2026-06-17H.C. WainwrightMatthew Caufield$872.4% upsideOpen
2026-05-21Leerink Partners$10115.5% upsideOpen
2026-03-11Craig-HallumAlbert Love$994% upsideOpen
2026-01-20BTIGThomas Shrader$750.9% upsideOpen
2025-11-25Piper Sandler$750.9% upsideOpen

Opus Genetics (IRD) FAQ

Opus Genetics (IRD) currently reports a target price of $13. Use the charts on this page to explore Opus Genetics's target price history and peer comparisons.

Analysts' average 12-month price target for Opus Genetics is $13, about 171.6% upside from the current share price of $4.64. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $13, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Opus Genetics, and consider following IRD for alerts when major investors trade the stock.

Opus Genetics is classified in the Healthcare sector. On target price, it currently shows $13. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IRD with unrelated industries.